BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7741044)

  • 1. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Matzke M; Pleiss U; Keldenich J; Müller-Peddinghaus R
    Agents Actions; 1994 Nov; 43(1-2):64-8. PubMed ID: 7741044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
    Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
    Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
    Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).
    Pergola C; Gerstmeier J; Mönch B; Çalışkan B; Luderer S; Weinigel C; Barz D; Maczewsky J; Pace S; Rossi A; Sautebin L; Banoglu E; Werz O
    Br J Pharmacol; 2014 Jun; 171(12):3051-64. PubMed ID: 24641614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly.
    Garscha U; Voelker S; Pace S; Gerstmeier J; Emini B; Liening S; Rossi A; Weinigel C; Rummler S; Schubert US; Scriba GK; Çelikoğlu E; Çalışkan B; Banoglu E; Sautebin L; Werz O
    Biochem Pharmacol; 2016 Nov; 119():17-26. PubMed ID: 27592027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
    Gür ZT; Çalışkan B; Banoglu E
    Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
    Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
    J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
    Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
    Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia depletion diminishes key elements of the leukotriene pathway in the brain of Alzheimer's Disease mice.
    Michael J; Unger MS; Poupardin R; Schernthaner P; Mrowetz H; Attems J; Aigner L
    Acta Neuropathol Commun; 2020 Aug; 8(1):129. PubMed ID: 32771067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocation of HL-60 cell 5-lipoxygenase. Inhibition of A23187- or N-formyl-methionyl-leucyl-phenylalanine-induced translocation by indole and quinoline leukotriene synthesis inhibitors.
    Kargman S; Prasit P; Evans JF
    J Biol Chem; 1991 Dec; 266(35):23745-52. PubMed ID: 1748650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.
    Ford-Hutchinson AW
    Trends Pharmacol Sci; 1991 Feb; 12(2):68-70. PubMed ID: 2024291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4).
    Surette ME; Krump E; Picard S; Borgeat P
    Mol Pharmacol; 1999 Nov; 56(5):1055-62. PubMed ID: 10531413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.
    Fiorucci S; Distrutti E; Mencarelli A; Morelli A; Laufor SA; Cirino G; Wallace JL
    Br J Pharmacol; 2003 Aug; 139(7):1351-9. PubMed ID: 12890715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of leukotrienes in inflammation and leukotriene inhibitors].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Matzke M; Pleiss U; Keldenich J; Müller-Peddinghaus R
    Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():23-31. PubMed ID: 7771337
    [No Abstract]   [Full Text] [Related]  

  • 18. Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B(4) in osteoarthritic chondrocytes: role of transforming growth factor beta and eicosanoids.
    Martel-Pelletier J; Mineau F; Fahmi H; Laufer S; Reboul P; Boileau C; Lavigne M; Pelletier JP
    Arthritis Rheum; 2004 Dec; 50(12):3925-33. PubMed ID: 15593193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.
    Fang WF; Douglas IS; Wang CC; Kao HC; Chang YT; Tseng CC; Huang KT; Chang HC; Lin MC
    PLoS One; 2014; 9(7):e102622. PubMed ID: 25025775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.
    Fischer L; Hornig M; Pergola C; Meindl N; Franke L; Tanrikulu Y; Dodt G; Schneider G; Steinhilber D; Werz O
    Br J Pharmacol; 2007 Oct; 152(4):471-80. PubMed ID: 17704828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.